These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 14604566)
1. Superiority of varicella skin test antigen over purified varicella-zoster virus glycoproteins in monitoring booster response to Oka varicella vaccine. Sato H; Yamamura Ji; Kageyama S; Kurokawa M; Shiraki K Vaccine; 2003 Dec; 22(1):15-20. PubMed ID: 14604566 [TBL] [Abstract][Full Text] [Related]
2. Immune response to varicella-zoster virus glycoproteins in guinea pigs infected with Oka varicella vaccine. Sato H; Kageyama S; Imakita M; Ida M; Yamamura J; Kurokawa M; Shiraki K Vaccine; 1998 Aug; 16(13):1263-9. PubMed ID: 9682389 [TBL] [Abstract][Full Text] [Related]
3. Delayed hypersensitivity skin test to detect susceptibility to varicella and zoster. Berger R; Luescher D; Just M; D'Hondt E; Bogaert H Postgrad Med J; 1985; 61 Suppl 4():137-41. PubMed ID: 3014471 [TBL] [Abstract][Full Text] [Related]
4. Neutralizing antibody responses induced by varicella-zoster virus gE and gB glycoproteins following infection, reactivation or immunization. Haumont M; Jurdan M; Kangro H; Jacquet A; Massaer M; Deleersnyder V; Garcia L; Bosseloir A; Bruck C; Bollen A; Jacobs P J Med Virol; 1997 Sep; 53(1):63-8. PubMed ID: 9298734 [TBL] [Abstract][Full Text] [Related]
5. Immune response to vaccinia virus recombinants expressing glycoproteins gE, gB, gH, and gL of Varicella-zoster virus. Kutinová L; Hainz P; Ludvíková V; Maresová L; Nĕmecková S Virology; 2001 Feb; 280(2):211-20. PubMed ID: 11162835 [TBL] [Abstract][Full Text] [Related]
6. The optimization and validation of the glycoprotein ELISA assay for quantitative varicella-zoster virus (VZV) antibody detection. Hammond O; Wang Y; Green T; Antonello J; Kuhn R; Motley C; Stump P; Rich B; Chirmule N; Marchese RD J Med Virol; 2006 Dec; 78(12):1679-87. PubMed ID: 17063506 [TBL] [Abstract][Full Text] [Related]
7. Construction of Oka varicella vaccine expressing human immunodeficiency virus env antigen. Shiraki K; Sato H; Yoshida Y; Yamamura JI; Tsurita M; Kurokawa M; Kageyama S J Med Virol; 2001 Jun; 64(2):89-95. PubMed ID: 11360239 [TBL] [Abstract][Full Text] [Related]
8. Antibodies to the three major glycoproteins of varicella-zoster virus: search for the relevant host immune response. Brunell PA; Novelli VM; Keller PM; Ellis RW J Infect Dis; 1987 Sep; 156(3):430-5. PubMed ID: 3039010 [TBL] [Abstract][Full Text] [Related]
9. Antibody assays suitable for assessing immune responses to live varicella vaccine. Provost PJ; Krah DL; Kuter BJ; Morton DH; Schofield TL; Wasmuth EH; White CJ; Miller WJ; Ellis RW Vaccine; 1991 Feb; 9(2):111-6. PubMed ID: 1647574 [TBL] [Abstract][Full Text] [Related]
10. Restoration of varicella-zoster virus cell-mediated immune response after varicella booster vaccination. Berger R; Luescher D; Just M Postgrad Med J; 1985; 61 Suppl 4():143-5. PubMed ID: 3014472 [TBL] [Abstract][Full Text] [Related]
11. Cell-mediated immune responses after immunization of healthy seronegative children with varicella vaccine: kinetics and specificity. Watson B; Keller PM; Ellis RW; Starr SE J Infect Dis; 1990 Oct; 162(4):794-9. PubMed ID: 2169495 [TBL] [Abstract][Full Text] [Related]
12. Serological detection of specific IgG to varicella-zoster virus by novel ELISA based on viral glycoprotein antigen. Sauerbrei A; Wutzler P Clin Lab; 2009; 55(1-2):1-7. PubMed ID: 19350844 [TBL] [Abstract][Full Text] [Related]
13. Biologic and immunologic characterization of the soluble skin-test antigen of varicella-zoster virus. Shiraki K; Yamanishi K; Takahashi M J Infect Dis; 1984 Apr; 149(4):501-4. PubMed ID: 6327833 [TBL] [Abstract][Full Text] [Related]
14. Serological detection of varicella-zoster virus-specific immunoglobulin G by an enzyme-linked immunosorbent assay using glycoprotein antigen. Sauerbrei A; Wutzler P J Clin Microbiol; 2006 Sep; 44(9):3094-7. PubMed ID: 16954232 [TBL] [Abstract][Full Text] [Related]
15. Cellular and humoral immunity to varicella zoster virus glycoproteins in immune and susceptible human subjects. Giller RH; Winistorfer S; Grose C J Infect Dis; 1989 Dec; 160(6):919-28. PubMed ID: 2555419 [TBL] [Abstract][Full Text] [Related]
16. Immunity to whole varicella-zoster virus antigen and glycoproteins I and p170: relation to the immunizing regimen of live attenuated varicella vaccine. Diaz PS; Smith S; Hunter E; Arvin AM J Infect Dis; 1988 Dec; 158(6):1245-52. PubMed ID: 2848901 [TBL] [Abstract][Full Text] [Related]
17. Seropositivity of Varicella zoster virus in vaccinated Korean children and MAV vaccine group. Choi UY; Huh DH; Kim JH; Kang JH Hum Vaccin Immunother; 2016 Oct; 12(10):2560-2564. PubMed ID: 27484734 [TBL] [Abstract][Full Text] [Related]
18. Immunization of the elderly and patients with collagen vascular diseases with live varicella vaccine and use of varicella skin antigen. Takahashi M; Iketani T; Sasada K; Hara J; Kamiya H; Asano Y; Baba K; Shiraki K J Infect Dis; 1992 Aug; 166 Suppl 1():S58-62. PubMed ID: 1320651 [TBL] [Abstract][Full Text] [Related]
19. Serologic analysis of the IgG antibody response in children with varicella zoster virus wild-type infection and vaccination. Jenke AC; Klein S; Baiker A; Wirth S; Sander M; Noelting C; Boecher O; Vizoso-Pinto MG Pediatr Infect Dis J; 2012 Nov; 31(11):1148-52. PubMed ID: 22863912 [TBL] [Abstract][Full Text] [Related]
20. A relationship between varicella-zoster virus-specific delayed hypersensitivity and varicella-zoster virus-induced anterior uveitis. Kezuka T; Sakai J; Minoda H; Takeuchi M; Keino H; Streilein JW; Usui M Arch Ophthalmol; 2002 Sep; 120(9):1183-8. PubMed ID: 12215092 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]